Beck Michael, Sanders James C, Ritt Philipp, Reinfelder Julia, Kuwert Torsten
Clinic of Nuclear Medicine, University of Erlangen-Nuremberg, Ulmenweg 18, 91054, Erlangen, Germany.
Pattern Recognition Lab, University of Erlangen-Nuremberg, Erlangen, Germany.
EJNMMI Res. 2016 Dec;6(1):60. doi: 10.1186/s13550-016-0217-4. Epub 2016 Jul 28.
The therapy response of osseous metastases (OM) is commonly monitored by bone scintigraphies (BS). The aim of this study was to compare visual evaluation of changes in tracer uptake with quantitation in absolute units in OMs; 52 OMs from 19 patients who underwent BS with SPECT/CT at time points one and two (TP1/2) were analyzed retrospectively, with an average of 10.3 months between TP1 and 2. Tracer uptake in lesions was visually compared by two independent readers in both planar scintigraphies and SPECT/CT across both TPs and classified as regressive, stable, or progressive. Quantitative analysis was performed by measuring peak standardized uptake values (SUV). Based on quantitation, lesions were similarly classified as regressive (>30 % decrease), progressive (>30 % increase), or stable (rest). If available, uptake in reference regions in the lower thoracic or lumbar spine was used for normalization.
In OMs at TP1 and TP2, mean SUVpeak (±SD) was found to be 20.4 (±20.8) and 16.4 (±11.5), respectively. For the reference region, mean SUVmean was 5.6 (±1.9) and 4.9 (±2.2). Agreement between quantitative and visual assessment was only moderate, with an average Cohen's kappa of 0.42 for planar scintigraphy and 0.62 for SPECT/CT. Discrepancies occurred in between 11 and 22 of the 52 lesions, depending on the reader and whether planar or SPECT imaging was considered.
Compared to measuring uptake in absolute units, visual evaluation of skeletal scintigraphies for change in tumor metabolism yields inconsistent results in roughly one third of the cases.
骨转移瘤(OM)的治疗反应通常通过骨闪烁显像(BS)进行监测。本研究的目的是比较骨转移瘤中示踪剂摄取变化的视觉评估与绝对单位的定量分析;回顾性分析了19例患者的52处骨转移瘤,这些患者在时间点一和时间点二(TP1/2)接受了单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)的骨闪烁显像,TP1和TP2之间的平均间隔时间为10.3个月。两名独立阅片者在两个时间点的平面闪烁显像和SPECT/CT中对病变的示踪剂摄取进行视觉比较,并分类为消退、稳定或进展。通过测量峰值标准化摄取值(SUV)进行定量分析。基于定量分析,病变同样被分类为消退(降低>30%)、进展(增加>30%)或稳定(其余)。如果可行,下胸椎或腰椎的参考区域摄取用于标准化。
在TP1和TP2的骨转移瘤中,平均SUV峰值(±标准差)分别为20.4(±20.8)和16.4(±11.5)。对于参考区域,平均SUV均值为5.6(±1.9)和4.9(±2.2)。定量评估和视觉评估之间的一致性仅为中等,平面闪烁显像的平均科恩kappa系数为0.42,SPECT/CT为0.62。根据阅片者以及是否考虑平面或SPECT成像,52处病变中有11至22处出现差异。
与以绝对单位测量摄取相比,对骨闪烁显像中肿瘤代谢变化进行视觉评估在大约三分之一的病例中产生不一致的结果。